Kinaxo adds new proteomics service
help drug developers decide which drug candidates to move through
the preclinical process.
The German services firm has added quantitative analysis to its KinaTor chemical proteomics platform, which it uses for the cellular profiling of kinase inhibitors. This cellular profiling service uses chemical proteomics technologies combined with mass spectrometry to identify a drug candidate's native molecular targets from cellular samples, in addition to the affinities of these interactions, in order to provide insight into its in vivo molecular target profile. The profiling service can also be useful in a number of other applications such as target identification, drug reprofiling and drug rescue, said the firm. "It is critically important that all biological interactions of a kinase inhibitor are evaluated, not just those with a subset of recombinant kinases," said Dr Klaus Godl Kinaxo's chief scientific officer. "The new service will enable not only the identification of drug candidate interactions with proteins derived from real cellular samples but importantly also their affinities thus supporting more informed lead candidate selection."
